Evotec

Evotec SE
Company typePublic
FWB: EVT
FWB: EVTA (ADR)
WBAG: EVT
Nasdaq: EVO (ADR)
MDAX component (FWB: EVT)
ISINDE0005664809
US30050E1055
IndustryBiotechnology, contract research organization
Founded1993; 31 years ago (1993)
FounderManfred Eigen
HeadquartersHamburg, Germany
Key people
  • Dr. Christian Wojczewski (CEO)
  • Iris Löw-Friedrich (chairwoman of the Supervisory Board)
Revenue618 million € (2021)[1]
Number of employees
>4,200 (2021)[1]
Websiteevotec.com

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion[2] and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.[3]

The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology (e.g. Alzheimer's disease, Huntington's disease), metabolic diseases (e.g. Diabetes), Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb,[4] Bayer,[5] Sanofi,[6] Boehringer Ingelheim,[7] the CHDI Foundation,[8] Lilly,[9] Takeda,[10] Sernova,[11] and more.

On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector.[12] On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing.[13] The MDAX tracks 60 Prime Standard shares from sectors excluding technology.[14] On 8 November 2021, Evotec completed its secondary listing on the U.S. Nasdaq stock exchange on November 8 and raised $500 million.[15]

  1. ^ a b "Evotec 2021 Annual Report" (PDF). evotec. Retrieved 12 April 2022.
  2. ^ "Evotec 2021 Annual Report" (PDF). evotec.com. Retrieved 12 April 2022.
  3. ^ "Evotec 2021 Annual Report" (PDF). evotec. Retrieved 12 April 2022.
  4. ^ "Evotec, Celgene Partner on Targeted Protein Degradation for Drug Discovery". GenomeWeb. Retrieved 5 December 2018.
  5. ^ "Bayer and Evotec Extend their Endometriosis Partnership". labiotech.eu. 24 July 2017. Retrieved 5 December 2018.
  6. ^ "Sanofi, Evotec in major infectious disease R&D transfer and license deal". FierceBiotech. Retrieved 24 November 2018.
  7. ^ "Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology". Evotec. Retrieved 25 January 2022.
  8. ^ "Evotec and CDHI form Huntington Disease alliance". Outsourcing-Pharma. 24 August 2006. Retrieved 24 November 2018.
  9. ^ "Evotec and Lilly enter into drug discovery collaboration in metabolic diseases". Evotec. Retrieved 18 January 2022.
  10. ^ "Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance". Evotec. Retrieved 22 March 2021.
  11. ^ "Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes". bionity. Retrieved 19 May 2022.
  12. ^ "Evotec Share". Boerse Frankfurt. Retrieved 13 December 2018.
  13. ^ "Evotec AG listed in MDAX". 16 May 2024.
  14. ^ "MDAX". Deutsche Boerse. Retrieved 13 December 2018.
  15. ^ "Evotec completed US IPO". Deutsche Boerse Cash Market. Retrieved 9 November 2021.